Oramorph Unit Dose Vial

Active Ingredient:: Morphine Sulfate Pentahydrate
Origin:: EU

Oramorph Unit Dose Vial (Morphine Sulfate Pentahydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Morphine sulfate, the active ingredient in Oramorph Unit Dose Vial, is an opioid analgesic presented as a sterile liquid for parenteral use. It is employed to manage moderate to severe pain in adult patients when other analgesics are insufficient.

GNH India supplies Oramorph Unit Dose Vial as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

L. Molteni And C. Dei F.Lli Alitti Società Di Esercizio S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Morphine sulfate is an opioid that acts on the central nervous system to relieve pain across several clinical contexts.

Acute postoperative pain: provides rapid analgesia following surgical procedures.
Cancer‑related pain: helps control persistent pain associated with malignant disease.
Severe chronic pain: used when long‑term opioid therapy is warranted for conditions such as advanced musculoskeletal disorders.

How It Works

Morphine sulfate is a full agonist at the μ‑opioid receptors in the central nervous system. Binding activates inhibitory G‑protein pathways, reducing neuronal excitability, decreasing neurotransmitter release, and altering pain perception pathways to produce analgesia.

Side Effects

Adverse reactions can range from mild to life‑threatening and should be monitored closely.

Common Side Effects

Nausea and vomiting: frequent gastrointestinal upset.
Constipation: reduced bowel motility leading to hard stools.
Drowsiness or sedation: increased sleepiness.
Pruritus: itching, often without rash.
Dry mouth: reduced salivation.
Urinary retention: difficulty emptying the bladder.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing that can be fatal.
Hypotension: marked drop in blood pressure.
Severe allergic reaction: anaphylaxis or angioedema.
Opioid dependence or withdrawal: signs of physical dependence with abrupt discontinuation.
Neurotoxicity: rare central nervous system disturbances such as seizures.
Cardiac arrhythmias: abnormal heart rhythms in susceptible individuals.

Precautions & Warnings

Morphine sulfate requires careful patient assessment and monitoring to minimise risks.

Assess pain severity and prior opioid exposure: determine appropriate need for strong opioid therapy.
Monitor respiratory function: watch for signs of depression, especially after dose initiation or escalation.
Evaluate renal and hepatic function: adjust use in patients with organ impairment.
Caution in the elderly: increased sensitivity to sedative and respiratory effects.
Avoid concurrent CNS depressants: limit use with benzodiazepines or alcohol.
Store at ambient temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Morphine sulfate can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines: combined use can cause profound respiratory depression.
Barbiturates: additive CNS depression may be life‑threatening.
Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

Anticholinergics: may worsen constipation.
Diuretics: can enhance hypotensive effects.
Certain antidepressants (e.g., SSRIs): may increase risk of serotonin syndrome.
CYP3A4 inhibitors (e.g., ketoconazole): may raise morphine plasma levels.
CYP3A4 inducers (e.g., rifampicin): may reduce analgesic effectiveness.

Frequently Asked Questions

Oramorph Unit Dose Vial contains morphine sulfate, an opioid analgesic used to treat moderate to severe pain, including postoperative pain, cancer‑related pain, and chronic pain that is not adequately controlled by weaker analgesics.

Morphine sulfate binds as a full agonist to μ‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that lower neuronal excitability and reduce the transmission of pain signals, resulting in analgesia.

The specific dose of Oramorph Unit Dose Vial is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and clinical condition. Dosing is individualized and should follow local prescribing guidelines.

Morphine crosses the placenta and is excreted in breast milk, so it is generally contraindicated unless the potential benefit justifies the risk. Use during pregnancy or lactation requires careful risk‑benefit assessment by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Oramorph (morphine sulfate) is a prototypical μ‑opioid receptor agonist, offering strong analgesia comparable to other potent opioids such as fentanyl or hydromorphone. Choice of agent depends on factors like route of administration, duration of action, patient tolerance, and specific clinical setting.

Store the vials at ambient temperature, protected from light and moisture, in their original packaging. Do not freeze. Follow standard aseptic handling procedures for parenteral products to maintain sterility.

The product is supplied as a sterile liquid for parenteral injection. It is administered intravenously or subcutaneously by a qualified healthcare professional, following aseptic technique and appropriate dosing calculations.

The most critical risks include respiratory depression, severe hypotension, opioid dependence, and rare but serious allergic reactions such as anaphylaxis. Continuous monitoring, especially after dose initiation or escalation, is essential to mitigate these risks.

Morphine sulfate is contraindicated in patients with known hypersensitivity to morphine or other opioids, those with significant respiratory depression, untreated obstructive sleep apnea, and in individuals taking mono‑mono‑mono‑MAO inhibitors. Clinical judgment is required for other contraindications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 07 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.